Until recently, few if any drugs for the treatment of neurologic diseases had achieved the dubious distinction of ranking among the ten most expensive drugs available in the United States in a given year. That's not to say that existing drugs for neurologic conditions aren't costly — the price of multiple sclerosis therapies has continued to increase over the years, for example, and in March 2017, the Food and Drug Administration (FDA) approved ocrelizumab, the first disease-modifying treatment specifically for primary progressive multiple sclerosis (PPMS), which has a price tag of approximately $65,000 before any negotiated discounts, at present oral drug for Multiple Sclerosis is available in India with a monthly cost of 45,000/- to 50,000/-INR in a month and annual cost of 5 lacs in a year approximately.
In 2017, however, neurology burst onto the list of most expensive drugs in a big…
